34658 Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis who had inadequate responses to apremilast at week 24 in the phase 3 POETYK PSO-1 and PSO-2 trials

Background: Deucravacitinib is an oral selective inhibitor of TYK2, which mediates signaling of key cytokines in psoriasis pathogenesis. The efficacy of deucravacitinib in patients with moderate to severe psoriasis who did not respond adequately to treatment with apremilast in 2 phase 3 trials was evaluated.